Clin2
NCT07175220Possibly a fitRecruiting

Study of SHR2554 tablets combined with other treatments for lung cancer

Locally Advanced or Metastatic Non-small Cell Lung Cancer

Part of Cancer, Lungs & breathing clinical trials.

This trial tests a new drug combination for people with non-small cell lung cancer that has spread or cannot be removed by surgery. It aims to see if adding SHR2554 tablets to other anticancer treatments can help control the disease.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
200 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have non-small cell lung cancer that has spread or can't be removed surgically.
  • You are able to take care of yourself (ECOG score 0 or 1).
  • Your organs are working well enough (kidneys, liver, etc.).
  • You have not had other cancer treatments within 4 weeks before starting this study.
  • You do not have active brain metastases or other serious health conditions.
  • You are not pregnant, breastfeeding, or planning to become pregnant during the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07229729Recruiting· Phase 2
Combination therapy for resectable lung cancer

This trial tests a new drug, SHR-A2102, combined with other treatments for people with non-small cell lung cancer that can be removed with surgery. It aims to improve outcomes by using multiple therapies together.

Guangzhou, Guangdong
NCT06589778Recruiting· Phase 1/Phase 2
Study of three drugs for advanced lung cancer

This trial tests a combination of three drugs (SHR-A2102, Adebrelimab, and SHR-8068) for people with advanced non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink or slow the growth of the cancer.

Shanghai, Shanghai Municipality
NCT06754930Recruiting· Phase 1/Phase 2
Study of SHR-1826 combined with other treatments for lung cancer

This trial tests a new drug called SHR-1826 in combination with other anti-cancer therapies for people with non-small cell lung cancer (NSCLC). It aims to see if these combinations are safe and effective for patients who haven't been treated before or whose cancer has come back.

Shanghai, Shanghai Municipality
NCT06512051Recruiting· Phase 1/Phase 2
Study of SHR-A2102 and Adebrelimab for advanced lung cancer

This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.

Beijing, Beijing Municipality
NCT05416775Recruiting· Phase 1/Phase 2
Test drug SHR-8068 for advanced lung cancer

This trial tests SHR-8068 in people with advanced non-small cell lung cancer (NSCLC). It may help by controlling cancer after standard treatments have not worked, and it’s designed to find the right way to give the drug.

Hefei, Anhui
NCT07170995Recruiting· Phase 3
Study of SHR-8068 with adebrelimab and chemo for lung cancer

This trial tests a new combination of drugs (SHR-8068 plus adebrelimab and chemotherapy) against another approved combination for people with advanced non-small cell lung cancer who have not had treatment yet. The goal is to see which combination works better.

Jinan, Shandong

Hear when a new Locally Advanced or Metastatic Non-small Cell Lung Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.